Furthermore, ANXA1 downregulates the expression of cyclooxygenase-2 (COX-2), leading to suppressed prostaglandin synthesis and reduced inducible nitric oxide synthase (iNOS) levels, reinforcing its anti-inflammatory role, with a significant contribution to cancer progression modulation [38,58]. The gene discussed is PTGS2; the disease is cancer.